Identification of Prognostic Risk Factors for Transient and Persistent Lymphedema after Multimodal Treatment for Breast Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study is to identify risk factors for transient lymphedema (TLE) and persistent lymphedema (PLE) following treatment for breast cancer. Materials and Methods A total of 1,073 patients who underwent curative breast surgery were analyzed. TLE was defined as one episode of arm swelling that had resolved spontaneously by the next followup; arm swelling that persisted over two consecutive examinations was considered PLE. Results At a median follow-up period of 5.1 years, 370 cases of lymphedema were reported, including 120 TLE (11.2%) and 250 PLE (23.3%). Initial grade 1 swelling was observed in 351 patients, of which 120 were limited to TLE (34%), while the other 231 progressed to PLE (66%). All initial swelling observed in TLE patients was classified as grade 1. In multivariate analysis, chemotherapy with taxane and supraclavicular radiation therapy (SCRT) were associated with development of TLE, whereas SCRT, stage III cancer and chemotherapy with taxane were identified as risk factors for PLE (p < 0.05). The estimated incidence of TLE among initial grade 1 patients was calculated using up to three treatment-related risk factors (number of dissected axillary lymph nodes, SCRT, and taxane chemotherapy). The approximate ratios of TLE and PLE based on the number of risk factors were 7:1 (no factor), 1:1 (one factor), 1:2 (two factors), and 1:3 (three factors). Conclusion One-third of initial swelling events were transient, whereas the other two-thirds of patients experienced PLE. Estimation of TLE and PLE based on known treatment factors could facilitate prediction of this life-long complication.
Abstract
Purpose The purpose of this study is to identify risk factors for transient lymphedema (TLE) and persistent lymphedema (PLE) following treatment for breast cancer. Materials and Methods A total of 1,073 patients who underwent curative breast surgery were analyzed. TLE was defined as one episode of arm swelling that had resolved spontaneously by the next followup; arm swelling that persisted over two consecutive examinations was considered PLE. Results At a median follow-up period of 5.1 years, 370 cases of lymphedema were reported, including 120 TLE (11.2%) and 250 PLE (23.3%). Initial grade 1 swelling was observed in 351 patients, of which 120 were limited to TLE (34%), while the other 231 progressed to PLE (66%). All initial swelling observed in TLE patients was classified as grade 1. In multivariate analysis, chemotherapy with taxane and supraclavicular radiation therapy (SCRT) were associated with development of TLE, whereas SCRT, stage III cancer and chemotherapy with taxane were identified as risk factors for PLE (p < 0.05). The estimated incidence of TLE among initial grade 1 patients was calculated using up to three treatment-related risk factors (number of dissected axillary lymph nodes, SCRT, and taxane chemotherapy). The approximate ratios of TLE and PLE based on the number of risk factors were 7:1 (no factor), 1:1 (one factor), 1:2 (two factors), and 1:3 (three factors). Conclusion One-third of initial swelling events were transient, whereas the other two-thirds of patients experienced PLE. Estimation of TLE and PLE based on known treatment factors could facilitate prediction of this life-long complication.
참고문헌 (19)
- DiSipio T, "Incidence of unilateral arm lymphoedema after breast cancer : a systematic review and meta-analysis", Lancet Oncol, 14, pp.500~515 (2013)
- Cemal Y, "Preventative measures for lymphedema : separating fact from fiction", J Am Coll Surg, 213, pp.543~551 (2011)
- Kim M, "A model to estimate the risk of breast cancer-related lymphedema : combinations of treatment-related factors of the number of dissected axillary nodes, adjuvant chemotherapy, and radiation therapy", Int J Radiat Oncol Biol Phys, 86, pp.498~503 (2013)
- Kilbreath SL, "Transient swelling versus lymphoedema in the first year following surgery for breast cancer", Support Care Cancer, 21, pp.2207~2215 (2013)
- Tsai RJ, "The risk of developing arm lymphedema among breast cancer survivors : a meta-analysis of treatment factors", Ann Surg Oncol, 16, pp.1959~1972 (2009)
- Brennan MJ, "Lymphedema following the surgical treatment of breast cancer : a review of pathophysiology and treatment", J Pain Symptom Manage, 7, pp.110~116 (1992)
- 박신형, "Virtual lymph node analysis to evaluate axillary lymph node coverage provided by tangential breast irradiation", Radiation oncology journal, 33(1), pp.50~56 (2015), 대한방사선종양학회
- Jung SY, "Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II", III breast cancer patients, 2014, pp.148, 91~98
- 김명수, "Breast Cancer–Related Lymphedema after Neoadjuvant Chemotherapy", Cancer Research and Treatment, 47(3), pp.416~423 (2015), 대한암학회[DOI]
- Gartner R, "Self-reported arm-lymphedema and functional impairment after breast cancer treatment : a nationwide study of prevalence and associated factors", Breast, 19, pp.506~515 (2010)
- Harris SR, "Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema", CMAJ, 164, pp.191~199 (2001)
- McLaughlin SA, "Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection : objective measurements", J Clin Oncol, 26, pp.5213~5219 (2008)
- Werner RS, "Arm edema in conservatively managed breast cancer : obesity is a major predictive factor", Radiology, 180, pp.177~184 (1991)
- Norman SA, "Lymphedema in breast cancer survivors : incidence, degree, time course, treatment, and symptoms", J Clin Oncol, 27, pp.390~397 (2009)
- Lee MJ, "Lymphedema following taxane-based chemotherapy in women with early breast cancer", Lymphat Res Biol, 12, pp.282~288 (2014)
- Dominick SA, "Risk factors associated with breast cancer-related lymphedema in the WHEL Study", J Cancer Surviv, 7, pp.115~123 (2013)
- Ahmed RL, "Risk factors for lymphedema in breast cancer survivors, the Iowa Women's Health Study", Breast Cancer Res Treat, 130, pp.981~991 (2011)
- Coen JJ, "Risk of lymphedema after regional nodal irradiation with breast conservation therapy", Int J Radiat Oncol Biol Phys, 55, pp.1209~1215 (2003)
- Bar Ad V, "Time course of mild arm lymphedema after breast conservation treatment for early-stage breast cancer", Int J Radiat Oncol Biol Phys, 76, pp.85~90 (2010)